Objective: To compare the incidence of multiple gestation following treatment with clomiphene citrate (CC), metformin (MET) or gonadotropins in polycystic ovary syndrome (PCOS) patients undergoing ovulation induction.
Study Design: This was a retrospective, cohort study performed in an academic reproductive endocrine practice. PCOS patients presenting for first-trimester ultrasound were identified and assigned to 1 of 3 groups: CC-resistant patients who conceived after use of metformin +/- CC (group A), CC-resistant patients who conceived after gonadotropins (group B) and PCOS patients who conceived with CC only (group C). Multiple pregnancy outcome data were collected by chart review and patient interview.
Results: One hundred one pregnancies were identified in PCOS patients who had conceived after ovulation induction (OI). The rate of multiple gestation was higher in group B (36%) than in A (0%) or C (11%).
Conclusion: The rate of multiple births was significantly lower with MET use during OI. Because multiple gestation is associated with higher complication rates and medical costs, our data offer an additional reason for use of MET for OI in PCOS patients who fail CC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prevalence of female hirsutism and PCOS in the United States: A cross-sectional study.
J Dtsch Dermatol Ges
January 2025
Department of Dermatology, Stony Brook University Medical Center, Stony Brook, New York, USA.
Background: Current research on hirsutism reveals disparities and knowledge deficiencies, particularly in underrepresented cohorts. Our objective is to scrutinize demographic variances in hirsutism rates.
Patients And Methods: Using the All of Us database, we conducted a cross-sectional analysis encompassing 172,401 women.
Unmet clinical needs in women with polycystic ovary syndrome regarding fertility and obesity: a cross-sectional study from the patient's perspective.
Arch Gynecol Obstet
January 2025
Division of Gynaecological Endocrinology and Reproductive Medicine, University Hospital Inselspital, Bern, Switzerland.
Purpose: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age, often leading to anovulatory infertility. Obesity exacerbates the reproductive, metabolic and psychological features of PCOS, making fertility treatment and patient satisfaction difficult. Despite guidelines from the European Society of Human Reproduction and Embryology (ESHRE) emphasizing lifestyle modifications and specific treatments, there remains a significant gap in adherence to these guidelines by both healthcare providers and patients.
View Article and Find Full Text PDFThe Role of Lifestyle Interventions in PCOS Management: A Systematic Review.
Nutrients
January 2025
Division of Reproductive Child Health and Nutrition, Indian Council of Medical Research (ICMR), New Delhi 110029, India.
Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders among reproductive-aged women. It is characterized by hyperandrogenism, anovulation, and polycystic ovaries. Lifestyle changes are suggested as first-line interventions in managing PCOS.
View Article and Find Full Text PDFEfficacy of -Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis.
Nutrients
January 2025
School of Medicine, Valencia Catholic University, C/Quevedo 2, 46001 Valencia, Spain.
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age and requires better treatment. -acetylcysteine (NAC) is known to be beneficial under such conditions owing to its antioxidant potential and insulin-sensitizing properties. The effect of NAC on the reproductive outcomes of PCOS patients was examined in this meta-analysis.
View Article and Find Full Text PDFThe Clinical Use of Myo-Inositol in IVF-ET: A Position Statement from the Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), the Polish Society of Andrology, and the International Scientific Association for the Support and Development of Medical Technologies.
J Clin Med
January 2025
The Experts Group on Inositol in Basic and Clinical Research, and on PCOS (EGOI-PCOS), 00161 Rome, Italy.
Myo-inositol plays a vital role in human health, functioning as a second messenger of FSH and facilitating the transport of glucose into the cell. Consequently, myo-inositol is regularly utilized in the treatment of polycystic ovary syndrome (PCOS), wherein it acts upon metabolic factors, improving insulin sensitivity and reducing total androgen levels. Patients with PCOS frequently suffer from infertility; thus, the use of myo-inositol has been explored in improving assistive reproductive technique (ART) procedures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!